ClinicalTrials.gg
CompletedNCT01068730Updated May 8, 2015Results posted

Bioequivalence Study of 500 mg and 1000 mg Glucophage (Metformin) Tablets in Healthy Subjects

A Phase 1 interventional study of metformin (Diabex) and metformin (Glucophage™) in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-08.

Sponsored by AstraZeneca · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.

Enrollment
231st of 287
28 · median 100
Started
2010
with 19 others
Phase 1
55 of 293
2 open now
Registered
101st of 293
by date
Lead sponsor
19 of 293
AstraZeneca

Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 231st largest by enrollment of the 287 interventional ones that give a count, is one of 20 that started in 2010, is one of 55 in phase 1, and was the 101st registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies testing metformin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

To demonstrate the bioequivalence of 500 mg and 1000 mg Glucophage tablets manufactured by BMS relative to the respective strengths of 500 mg and 1000 mg Diabex tablets marketed in Australia by Alphapharm in the fed state

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ages 18 to 55 inclusive
  • Healthy subjects as determined by no deviation from normal in medical history, physical examination, (ECGs), and clinical laboratory determinations
  • (BMI) of 18 to 32 kg/m², inclusive. BMI = weight (kg)/ [height (m)]²

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical illness
  • Current or recent (within 3 months) gastrointestinal disease
  • Any major surgery within 4 weeks of study drug administration
  • History of allergy or intolerance to metformin or other similar acting agents
  • Prior exposure to metformin within 3 months of study drug administration
  • Estimated (Clcr) of \< 80ml/min using the Cockcroft Gault formula
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Other
    Treatment A

    500 mg metformin (Diabex): Single oral dose of 500 mg metformin (Diabex) tablet administered in the fed condition

    Drug: metformin (Diabex)

  • Other
    Treatment B

    500 mg metformin (Glucophage™): Single oral dose of 500 mg metformin (Glucophage™) tablet administered in the fed condition

    Drug: metformin (Glucophage™)

  • Other
    Treatment C

    1000 mg metformin (Diabex): Single oral dose of 1000 mg metformin (Diabex) tablet administered in the fed condition

    Drug: metformin (Diabex)

  • Other
    Treatment D

    1000 mg metformin (Glucophage™): A Single oral dose of 1000 mg metformin (Glucophage™) tablet administered in the fed condition

    Drug: metformin (Glucophage™)

Interventions

06

What researchers measure

Primary outcomes

  1. Metformin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.

    Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing

  2. Metformin PK Parameter Observed Maximum Plasma Concentration (Cmax)

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.

    Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing

Secondary outcomes

  1. Participants With Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs)

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.

    Time frame: AEs: from study drug administration Day 1/Period 1 till study discharge. SAEs: from date of written consent until 30 days after discontinuation of dosing or study participation. Duration of the study was approximately 45 days (including screening).

  2. Participants With Electrocardiogram Abnormalities Considered Clinically Significant or Reported as an AE

    Clinically significant was determined by the investigator. ECGs were recorded after participants had been supine for at least 5 minutes.

    Time frame: From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).

  3. Participants With Abnormal Physical Findings

    Physical findings that were considered abnormal by the investigator.

    Time frame: From Day 1/Period 1 to study discharge or premature discontinuation. Duration of study was approximately 45 days (including screening).

  4. Participants With Abnormal Vital Sign Findings Reported as an AE

    per investigator

    Time frame: From Day 1/Period 1 to study discharge or premature discontinuation. Duration of study was approximately 45 days (including screening).

  5. Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Hematology

    Clinically significant was determined by the investigator.

    Time frame: From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).

  6. Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Serum Chemistry

    Clinically significant was determined by the investigator.

    Time frame: From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).

  7. Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Urinalysis

    Clinically significant was determined by the investigator.

    Time frame: From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).

Other outcomes

  1. Metformin Pharmacokinetic (PK) Parameter Time to Achieve the Observed Maximum Plasma Concentration (Tmax)

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.

    Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing

  2. Metformin Pharmacokinetic (PK) Parameter Terminal Half-life (T 1/2)

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma

    Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing

  3. Metformin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC\[0-t\] is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.

    Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing

07

Results

Posted Mar 29, 2012

Participant flow

A total of 28 participants who met all of the inclusion and none of the exclusion criteria were planned and enrolled in the study from a single site in the United States.

Period 1
Participant flow — Period 1
MilestoneTreatment Sequence ADBCTreatment Sequence BACDTreatment Sequence CBDATreatment Sequence DCAB
Started7777
Completed7777
Not completed0000
Period 2
Participant flow — Period 2
MilestoneTreatment Sequence ADBCTreatment Sequence BACDTreatment Sequence CBDATreatment Sequence DCAB
Started7777
Completed7777
Not completed0000
Period 3
Participant flow — Period 3
MilestoneTreatment Sequence ADBCTreatment Sequence BACDTreatment Sequence CBDATreatment Sequence DCAB
Started7777
Completed6777
Not completed1000
Withdrew: Personal reason1000
Period 4
Participant flow — Period 4
MilestoneTreatment Sequence ADBCTreatment Sequence BACDTreatment Sequence CBDATreatment Sequence DCAB
Started6777
Completed6677
Not completed0100
Withdrew: Family emergency0100

Outcome measures

PrimaryMetformin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.

Time frame:
Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Reported as:
Geometric mean · ng*hr/mL
Metformin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])
ng*hr/mLTreatment A - 500 mg DiabexTreatment B - 500 mg GlucophageTreatment C - 1000 mg DiabexTreatment D - 1000 mg Glucophage
Metformin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])7062.76 ± 26.917187.14 ± 25.9511577.85 ± 27.3611424.73 ± 29.06
Statistical analysis
  • Treatment A - 500 mg Diabex vs Treatment B - 500 mg Glucophage · Ratio (%) of geometric ls means: 102.58 · 95% CI 99.07 to 106.23Ratio=Treatment B/Treatment A. Geometric least squares (LS) means values are presented in other statistical analysis entries.
  • Treatment C - 1000 mg Diabex vs Treatment D - 1000 mg Glucophage · Ratio (%) of geometric ls means: 99.67 · 95% CI 96.16 to 103.31Ratio=Treatment D/Treatment C. Geometric LS means values are presented in other statistical analysis entries.
  • Treatment A - 500 mg Diabex · Geometric least squares mean (ng*hr/ml): 7062.8
  • Treatment B - 500 mg Glucophage · Geometric least squares mean (ng*hr/ml): 7245.2
  • Treatment C - 1000 mg Diabex · Geometric least squares mean (ng*hr/ml): 11680
  • Treatment D - 1000 mg Glucophage · Geometric least squares mean (ng*hr/ml)]: 11641
PrimaryMetformin PK Parameter Observed Maximum Plasma Concentration (Cmax)

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.

Time frame:
Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Reported as:
Geometric mean · ng/mL
Metformin PK Parameter Observed Maximum Plasma Concentration (Cmax)
ng/mLTreatment A - 500 mg DiabexTreatment B - 500 mg GlucophageTreatment C - 1000 mg DiabexTreatment D - 1000 mg Glucophage
Metformin PK Parameter Observed Maximum Plasma Concentration (Cmax)1013.57 ± 25.671019.59 ± 25.261635.30 ± 27.671593.20 ± 26.87
Statistical analysis
  • Treatment A - 500 mg Diabex vs Treatment B - 500 mg Glucophage · Ratio (%) of geometric ls means: 101.12 · 95% CI 96.36 to 106.11Ratio=Treatment B/Treatment A. Geometric LS means values are presented in other statistical analysis entries.
  • Treatment C - 1000 mg Diabex vs Treatment D - 1000 mg Glucophage · Ratio (%) of geometric ls means: 98.65 · 95% CI 93.94 to 103.59Ratio=Treatment B/Treatment A. Geometric LS means values are presented in other statistical analysis entries.
  • Treatment A - 500 mg Diabex · Geometric least squares mean (ng/ml): 1013.6
  • Treatment B - 500 mg Glucophage · Geometric least squares mean (ng/ml): 1024.9
  • Treatment C - 1000 mg Diabex · Geometric least squares mean (ng/ml): 1643.8
  • Treatment D - 1000 mg Glucophage · Geometric least squares mean (ng/ml): 1621.6
SecondaryParticipants With Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs)

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.

Time frame:
AEs: from study drug administration Day 1/Period 1 till study discharge. SAEs: from date of written consent until 30 days after discontinuation of dosing or study participation. Duration of the study was approximately 45 days (including screening).
Reported as:
Number · Participants
Participants With Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs)
ParticipantsTreatment A - 500 mg DiabexTreatment B - 500 mg GlucophageTreatment C - 1000 mg DiabexTreatment D - 1000 mg Glucophage
Participants With atleast 1 Treatment-emergent AE6256
Discontinuations Due to AE0000
Deaths0000
SAEs0000
SecondaryParticipants With Electrocardiogram Abnormalities Considered Clinically Significant or Reported as an AE

Clinically significant was determined by the investigator. ECGs were recorded after participants had been supine for at least 5 minutes.

Time frame:
From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).
Reported as:
Number · Participants
Participants With Electrocardiogram Abnormalities Considered Clinically Significant or Reported as an AE
ParticipantsTreatment A - 500 mg DiabexTreatment B - 500 mg GlucophageTreatment C - 1000 mg DiabexTreatment D - 1000 mg Glucophage
Participants With Electrocardiogram Abnormalities Considered Clinically Significant or Reported as an AE0 ± 00 ± 00 ± 00 ± 0
SecondaryParticipants With Abnormal Physical Findings

Physical findings that were considered abnormal by the investigator.

Time frame:
From Day 1/Period 1 to study discharge or premature discontinuation. Duration of study was approximately 45 days (including screening).
Reported as:
Number · Participants
Participants With Abnormal Physical Findings
ParticipantsTreatment A - 500 mg DiabexTreatment B - 500 mg GlucophageTreatment C - 1000 mg DiabexTreatment D - 1000 mg Glucophage
Participants With Abnormal Physical Findings0000
SecondaryParticipants With Abnormal Vital Sign Findings Reported as an AE

per investigator

Time frame:
From Day 1/Period 1 to study discharge or premature discontinuation. Duration of study was approximately 45 days (including screening).
Reported as:
Number · Participants
Participants With Abnormal Vital Sign Findings Reported as an AE
ParticipantsTreatment A - 500 mg DiabexTreatment B - 500 mg GlucophageTreatment C - 1000 mg DiabexTreatment D - 1000 mg Glucophage
Participants With Abnormal Vital Sign Findings Reported as an AE0000
Other pre-specifiedMetformin Pharmacokinetic (PK) Parameter Time to Achieve the Observed Maximum Plasma Concentration (Tmax)

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.

Time frame:
Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Reported as:
Mean · hr
Metformin Pharmacokinetic (PK) Parameter Time to Achieve the Observed Maximum Plasma Concentration (Tmax)
hrTreatment A - 500 mg DiabexTreatment B - 500 mg GlucophageTreatment C - 1000 mg DiabexTreatment D - 1000 mg Glucophage
Metformin Pharmacokinetic (PK) Parameter Time to Achieve the Observed Maximum Plasma Concentration (Tmax)3.25 ± 0.793.56 ± 0.803.22 ± 0.643.23 ± 0.80
Other pre-specifiedMetformin Pharmacokinetic (PK) Parameter Terminal Half-life (T 1/2)

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma

Time frame:
Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Reported as:
Mean · hr
Metformin Pharmacokinetic (PK) Parameter Terminal Half-life (T 1/2)
hrTreatment A - 500 mg DiabexTreatment B - 500 mg GlucophageTreatment C - 1000 mg DiabexTreatment D - 1000 mg Glucophage
Metformin Pharmacokinetic (PK) Parameter Terminal Half-life (T 1/2)13.2310 ± 5.318011.5349 ± 3.763312.6152 ± 4.203212.5268 ± 4.3137
SecondaryParticipants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Hematology

Clinically significant was determined by the investigator.

Time frame:
From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).
Reported as:
Number · Participants
Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Hematology
ParticipantsTreatment A - 500 mg DiabexTreatment B - 500 mg GlucophageTreatment C - 1000 mg DiabexTreatment D - 1000 mg Glucophage
Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Hematology0000
SecondaryParticipants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Serum Chemistry

Clinically significant was determined by the investigator.

Time frame:
From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).
Reported as:
Number · Participants
Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Serum Chemistry
ParticipantsTreatment A - 500 mg DiabexTreatment B - 500 mg GlucophageTreatment C - 1000 mg DiabexTreatment D - 1000 mg Glucophage
Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Serum Chemistry0000
SecondaryParticipants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Urinalysis

Clinically significant was determined by the investigator.

Time frame:
From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).
Reported as:
Number · Participants
Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Urinalysis
ParticipantsTreatment A - 500 mg DiabexTreatment B - 500 mg GlucophageTreatment C - 1000 mg DiabexTreatment D - 1000 mg Glucophage
Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Urinalysis0000
Other pre-specifiedMetformin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC\[0-t\] is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.

Time frame:
Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Reported as:
Geometric mean · ng*hr/mL
Metformin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])
ng*hr/mLTreatment A - 500 mg DiabexTreatment B - 500 mg GlucophageTreatment C - 1000 mg DiabexTreatment D - 1000 mg Glucophage
Metformin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])6907.06 ± 27.167078.70 ± 26.1811305.27 ± 27.7711129.89 ± 28.93
Statistical analysis
  • Treatment A - 500 mg Diabex vs Treatment B - 500 mg Glucophage · Ratio (%) of geometric ls means: 103.19 · 95% CI 99.75 to 106.75Ratio=Treatment B/Treatment A. Geometric LS means values are presented in other statistical analysis entries.
  • Treatment C - 1000 mg Diabex vs Treatment D - 1000 mg Glucophage · Ratio (%) of geometric ls means: 99.44 · 95% CI 96.08 to 102.92Ratio=Treatment D/Treatment C. Geometric LS means values are presented in other statistical analysis entries.
  • Treatment A - 500 mg Diabex · Geometric least squares mean (ng*hr/ml): 6907.1
  • Treatment B - 500 mg Glucophage · Geometric least squares mean (ng*hr/ml): 7127.4
  • Treatment C - 1000 mg Diabex · Geometric least squares mean (ng*hr/ml): 11391
  • Treatment D - 1000 mg Glucophage · [geometric least squares mean (ng*hr/ml): 11327

Adverse events

Collected over From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment C - 1000 mg Diabex—0/27 (0%)5/27 (18.5%)
Treatment D - 1000 mg Glucophage—0/27 (0%)6/27 (22.2%)
Treatment A - 500 mg Diabex—0/28 (0%)6/28 (21.4%)
Treatment B - 500 mg Glucophage—0/27 (0%)2/27 (7.4%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventTreatment C - 1000 mg DiabexTreatment D - 1000 mg GlucophageTreatment A - 500 mg DiabexTreatment B - 500 mg Glucophage
Vascular access complicationInjury, poisoning and procedural complications2/274/272/281/27
DiarrhoeaGastrointestinal disorders2/272/271/280/27
Abdominal painGastrointestinal disorders1/272/272/281/27
HeadacheNervous system disorders0/271/271/280/27
DizzinessNervous system disorders1/271/270/280/27
SomnolenceNervous system disorders0/271/270/280/27
NauseaGastrointestinal disorders0/271/270/280/27
FlatulenceGastrointestinal disorders0/271/271/280/27
Decreased appetiteMetabolism and nutrition disorders1/270/270/281/27
PruritusSkin and subcutaneous tissue disorders0/271/270/280/27

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Enrolled and Treated Participants
Mean34.6 ± 11.05
Sex: Female, Male
Sex: Female, Male(Participants)All Enrolled and Treated Participants
Female12
Male16
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Enrolled and Treated Participants
White24
Black or African American4
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Enrolled and Treated Participants
Hispanic or Latino10
Not Hispanic or Latino18
Height
Height(Centimeter)All Enrolled and Treated Participants
Mean169.54 ± 11.44
Weight
Weight(kg)All Enrolled and Treated Participants
Mean77.02 ± 15.88
Body Mass Index
Body Mass Index(kg/m^2)All Enrolled and Treated Participants
Mean26.58 ± 3.64
08

Study locations

1 site
  • PPD Development, LP
    Austin, Texas 78744, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2010
First posted
Feb 15, 2010
Start
Feb 2010
Primary completionActual
Apr 2010
CompletionActual
Apr 2010
Results first posted
Mar 29, 2012
Last update
May 8, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01068730
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 15, 2010
Start date
Feb 2010
Primary completion
Apr 2010
Completion
Apr 2010
Results posted
Mar 29, 2012
Last update
May 8, 2015

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion